Up-front Testing Is Imperative for Treatment Decisions in RET+ NSCLC

Deborah B. Doroshow, MD, PhD, discusses the efficacy and toxicity profiles of pralsetinib and selpercatinib and how they influence treatment selection for patients with RET fusion–positive non–small cell lung cancer, and provides insight on several areas of ongoing or potential research in lung cancer.

Related Keywords

New York ,United States ,Deborahb Doroshow , ,Foundation Medicine Clinico ,International Lung Cancer Congress ,Icahn School Of Medicine At Mount Sinai ,Tisch Cancer Institute ,Annual International Lung Cancer Congress ,Icahn School ,Mount Sinai ,Flatiron Foundation Medicine Clinico Genomics ,Pralsetinib ,Selpercatinib ,D ,Phd ,Ilcc ,Non Small Cell Lung Cancer ,Nsclc ,Bret ,Ret Fusions ,Ret Positive Lung Cancer ,